Effectiveness and cost-effectiveness of 4 supplementary foods for treating moderate acute malnutrition: result from a cluster-randomized intervention trail in Sierra Leone

Background: Moderate acute malnutrition (MAM) affects 33 million children annually. Investments in formulations of corn-soyblended flours and lipid-based nutrient supplements have effectively improved MAM recovery rates. Information costs and cost-effectiveness differences are still needed. Objectives: We assessed recovery and sustained recovery rates of MAM children receiving a supplementary food: ready-to-usesupplementary food (RUSF), corn soy whey blend with fortified vegetable oil (CSWB w/oil), or Super Cereal Plus with amylase(SC + A) compared to Corn Soy Blend Plus with fortified vegetable oil (CSB+ w/oil). We also estimated differences in costs and cost-effectiveness of each supplement. Methods: In Sierra Leone, we randomly assigned 29 health centers to provide a supplement containing 550 kcal/d for similar to 12 wk to 2691 children with MAM aged 6-59 mo. We calculated cost perenrollee, cost per child who recovered, and cost per child who sustained recovery each from 2 perspectives: program perspective and caregiver perspective, combined. Results: Of 2653 MAM children (98.6%) with complete data, 1676 children (63%) recovered. There were no significant differences in the odds of recovery compared to CSB+ w/oil [0.83 (95% CI: 0.64-1.08)for CSWB w/oil, 1.01 (95% CI: 0.78-1.3) for SC + A, 1.05(95% CI: 0.82-1.34) for RUSF]. The odds of sustaining recovery were significantly lower for RUSF (0.7; 95% CI 0.49-0.99) but not CSWB w/oil or SC + A [1.08 (95% CI: 0.73-1.6) and 0.96 (95% CI:0.67-1.4), respectively] when compared to CSB+ w/oil. Costs perenrollee [US dollars (USD)/child] ranged from $105/child in RUSF to $112/child in SC + A and costs per recovered child (USD/child)ranged from $163/child in RUSF to $179/child in CSWB w/oil, with overlapping uncertainty ranges. Costs were highest per sustained recovery (USD/child), ranging from $214/child with the CSB+ w/oilto $226/child with the SC + A, with overlapping uncertainty ranges. Conclusions: The 4 supplements performed similarly across recovery(but not sustained recovery) and costed measures. Analyses of posttreatment outcomes are necessary to estimate the full cost of MAM treatment.